



**PTCTC Fall In-Person Meeting Presentations**  
**New Orleans Marriott: 555 Canal Street, New Orleans, LA.**  
**Mardi Gras Ballroom- Salon D-E**  
**Tuesday, September 20, 2022**  
**(8:20am – 3:15pm CT)**

**AGENDA**

<b>Time (CT)</b>	<b>Presentation</b>	<b>Chair</b>
7:15 – 8:20am	<b>Registration and Breakfast</b>	
8:20-8:30am	Welcome address	Leslie Kean, MD, PhD
8:30 – 9:15am	Oncology	Troy Quigg, DO, MS
9:15 – 10:00am	Supportive Care	Sung Won Choi, MD, MS
10-10:15am	Break	
10:15 – 11:00am	GVHD	Kirsten Williams, MD
11:00 – 11:45am	Late Effects	Christine Duncan, MD
11:45am – 12:00pm	<b>Lunch</b>	
12:15 – 1:15pm	Top-down and Bottom-up approaches to understand host-associated microbiomes	Seth Rakoff-Nahoum, MD, PhD
1:15 – 2:00pm	Cellular Therapeutics	Nirali Shah, MD, MHSc
2:00 – 2:45pm	Non-Malignant Disease	Sung-Yun Pai, MD
2:45 – 3:15pm	<b>Closing remarks</b>	Leslie Kean, MD, PhD Michael Verneris, MD
<b>MEETING ADJOURNED</b>		

## ONCOLOGY STRATEGY GROUP SESSION

8:30-9:15 am

Chair Troy Quigg, DO, MS

Vice Chair Alix Seif, MD, MPH

Topic	Presenter
ONC1701/EndRAD: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children and Young Adults with B-ALL (EndRAD) Study PIs: Abdel-Azim/Quigg	Hisham Abdel-Azim MD, MS
Pilot Study using Induction Chemo-immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-cell or NK Lymphoma/Leukemia in Children, Adolescents, And Young Adults Study PIs: Cairo/Xavier	Troy Quigg DO, MS/ Alix Seif, MD, MPH
A Phase 1/2 Trial of Uproleselan Combined with High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients with Chemotherapy Resistant Acute Myeloid Leukemia Study PIs: Horan/Chewning	Troy Quigg DO, MS/ Alix Seif, MD, MPH
ALLO-T-DART: A Phase I Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) Study PIs: Quigg/Flower/Cairo	Troy Quigg, DO, MS

## SUPPORTIVE CARE STRATEGY GROUP SESSION

9:15-10:00 am

Chair: Sung Won Choi, MD, MS

Vice Chair: Akshay Sharma, MBBS

Topic	Presenter
Using ultrasound elastography to predict development of hepatic sinusoidal obstruction syndrome: PI: Sherwin Chang MD	Sung Won Choi, MD, MS Chris Dandoy MD MS
Olanzapine for chemotherapy-induced vomiting in children receiving highly emetic chemotherapy PI: Lee Dupuis RPh PhD	Sung Won Choi, MD, MS Chris Dandoy MD MS
Assessment of fertility potential in survivors of reduced intensity HCT: PI: Seth Rotz MD	Sung Won Choi, MD, MS Chris Dandoy MD MS
QI Initiatives (Updates on TMA, Neuroblastoma, and TALNT): Chris Dandoy MD MS	Chris Dandoy MD MS
Impact of trimethoprim/sulfamethoxazole prophylaxis on engraftment in pediatric allogeneic hematopoietic cell transplant recipients: PI Amanda Lipsitt MD	Sung Won Choi, MD, MS

**GRAFT VERSES HOST DISEASE STRATEGY GROUP SESSION****10:15 -11:00 am****Chair:** Kirsten Williams, MD**Vice Chair:** Geoffrey Cuvelier, MD

Topic	Presenter
<u>A</u> pplied <u>B</u> iomarkers in <u>L</u> ate <u>E</u> ffects of Childhood Cancer Treatment (ABLE2.0)	Kirk Schultz, MD
Acute GVHD Suppression using Costimulation Blockade to Expand Non-Malignant Transplant (ASCENT)	Leslie Kean, MD, PhD
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenic Blood and Marrow Transplantation (NCT03842696)	Sung Won Choi, MD, MS
MAGIC Biomarker Study in Pediatric Patients	Carrie Kitko, MD
Joint proposal with the PTCTC Late Effects strategy group	Kirsten Williams, MD/Geoff Cuvelier, MD

**LATE EFFECTS STRATEGY GROUP SESSION****11:00-11:45 am****Chair:** Christine Duncan, MD**Vice Chair:** Seth Rotz, MD

Topic	Presenter
Neurocognition and Frailty Study PI: Rachel Phelan, Hesham Eissa	Christine Duncan, MD
PROSPECT: PROSpective evaluation of delayed effects of PEdiatric CAR T cell therapy Study PI: Nirali Shah/ Rebecca Gardner	Christine Duncan, MD
Concepts in Development	Christine Duncan, MD
Outcomes and Late-Effects/ GVHD Consensus Conference	Christine Duncan, MD /Seth Rotz, MD
ASTCT Recommended Screening and Preventive Practices for Long-Term survivors after Hematopoietic Cell Transplantation: 2022 Update	Seth Rotz, MD

## CELLULAR THERAPEUTICS STRATEGY GROUP SESSION

**1:15-2:00 pm**

**Chair:** Nirali Shah, MD MHSc

**Vice Chair:** Michael Keller, MD

Topic	Presenter
<ol style="list-style-type: none"><li>1. Introductions and General overview<ol style="list-style-type: none"><li>a. Including a call for new folks to join if interested</li></ol></li><li>2. Recently Completed Studies: ACES</li><li>3. Actively Enrolling Studies:<ol style="list-style-type: none"><li>a. CD33 CAR</li><li>b. EXCEL</li><li>c. CTLs</li></ol></li><li>4. Future Studies:<ol style="list-style-type: none"><li>a. CAR-CURE</li><li>b. New topics</li></ol></li></ol>	Michael Keller, MD

## NON-MALIGNANT DISEASE STRATEGY GROUP SESSION

**2:00-2:45pm**

**Chair:** Sung -Yun Pai, MD

**Vice Chair:** Monica Bhatia, MD

Topic	Presenter
NMD 1801: Conditioning SCID Infants Diagnosed Early: A randomized trial of low versus moderate exposure busulfan & TCR $\alpha\beta$ + /CD19+ depleted transplantation	Michael Pulsipher, MD
NMD 1601: Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT)	Michael Pulsipher, MD
Minimizing Toxicity in HLA-identical Sibling Transplant for Pediatric Sickle Cell Disease – the SUN study	Greg Guilcher, MD
CNI Free GVHD prophylaxis using Abatacept and Post-Transplant Cyclophosphamide for HLA-matched RIC HCT for SCD	Greg Guilcher, MD